Published in Antimicrob Agents Chemother on November 01, 1998
A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother (2000) 8.54
Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev (2002) 3.27
Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug. J Virol (2000) 2.27
Impact of distal mutations on the network of coupled motions correlated to hydride transfer in dihydrofolate reductase. Proc Natl Acad Sci U S A (2005) 2.05
Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J Virol (2001) 2.04
Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes. Proc Natl Acad Sci U S A (2001) 1.64
In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob Agents Chemother (2000) 1.59
Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease. Protein Sci (2002) 1.49
Viability of a drug-resistant human immunodeficiency virus type 1 protease variant: structural insights for better antiviral therapy. J Virol (2003) 1.37
Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy. J Clin Microbiol (2000) 1.35
Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother (2004) 1.31
Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrob Agents Chemother (2002) 1.27
BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob Agents Chemother (2000) 1.26
Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease. J Virol (2002) 1.17
Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob Agents Chemother (2000) 1.17
The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors. AIDS Rev (2000) 1.15
Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France. J Clin Microbiol (2004) 1.15
ACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatments for HIV-1. Control Clin Trials (2001) 1.07
Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance. J Virol (2009) 1.07
Susceptibility of the porcine endogenous retrovirus to reverse transcriptase and protease inhibitors. J Virol (2001) 0.95
A bacteriophage lambda-based genetic screen for characterization of the activity and phenotype of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother (2000) 0.95
In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. Antimicrob Agents Chemother (2007) 0.94
Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones. Antimicrob Agents Chemother (2005) 0.94
Comprehensive bioinformatic analysis of the specificity of human immunodeficiency virus type 1 protease. J Virol (2005) 0.93
Design and synthesis of stereochemically defined novel spirocyclic P2-ligands for HIV-1 protease inhibitors. Org Lett (2008) 0.88
Functional correlates of insertion mutations in the protease gene of human immunodeficiency virus type 1 isolates from patients. J Virol (2001) 0.87
Comparison of human immunodeficiency virus type 1 Pr55(Gag) and Pr160(Gag-pol) processing intermediates that accumulate in primary and transformed cells treated with peptidic and nonpeptidic protease inhibitors. Antimicrob Agents Chemother (2000) 0.83
Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy. Antimicrob Agents Chemother (2001) 0.77
HIV-1 protease has a genetic T-cell adjuvant effect which is negatively regulated by proteolytic activity. J Virol (2010) 0.75
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (1995) 34.97
Viral dynamics in human immunodeficiency virus type 1 infection. Nature (1995) 28.54
HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science (1995) 18.40
On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun (1967) 18.32
Rapid evolution of RNA genomes. Science (1982) 14.76
Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1989) 12.54
Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci U S A (1988) 10.77
Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature (1988) 10.69
In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature (1995) 10.13
Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol (1995) 9.02
Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science (1989) 7.15
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med (1996) 6.14
A deletion mutation in the 5' part of the pol gene of Moloney murine leukemia virus blocks proteolytic processing of the gag and pol polyproteins. J Virol (1985) 5.78
Recombination in HIV-1. Nature (1995) 5.72
A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother (1998) 5.64
Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J Virol (1989) 5.15
Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature (1989) 4.80
Structure-based inhibitors of HIV-1 protease. Annu Rev Biochem (1993) 4.80
Murine leukemia virus maturation: protease region required for conversion from "immature" to "mature" core form and for virus infectivity. Virology (1985) 4.65
Rational design of peptide-based HIV proteinase inhibitors. Science (1990) 4.57
Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol (1996) 4.45
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med (1996) 4.43
Properties of avian retrovirus particles defective in viral protease. J Virol (1990) 4.03
Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor. Proc Natl Acad Sci U S A (1987) 3.72
Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol (1997) 3.64
Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J Virol (1994) 3.45
Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol (1996) 3.39
HTLV-III gag protein is processed in yeast cells by the virus pol-protease. Science (1986) 3.06
Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol (1995) 3.05
A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med (1995) 3.04
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci U S A (1994) 3.00
Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. J Virol (1993) 2.96
Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry (1995) 2.90
A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med (1995) 2.88
Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution. Science (1989) 2.74
Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother (1998) 2.67
In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. J Infect Dis (1996) 2.34
Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology (1995) 2.29
Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother (1995) 2.21
Human immunodeficiency virus type 1 subtypes defined by env show high frequency of recombinant gag genes. The UNAIDS Network for HIV Isolation and Characterization. J Virol (1996) 2.17
Dual human immunodeficiency virus type 1 infection and recombination in a dually exposed transfusion recipient. The Transfusion Safety Study Group. J Virol (1995) 2.15
Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS (1996) 2.14
HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins. Biochem Biophys Res Commun (1988) 2.14
Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother (1996) 2.13
Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J Med Chem (1997) 2.04
Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity. J Biol Chem (1996) 1.94
HIV protease: a novel chemotherapeutic target for AIDS. J Med Chem (1991) 1.90
HIV inhibitors targeted at the reverse transcriptase. AIDS Res Hum Retroviruses (1992) 1.90
Flap opening in HIV-1 protease simulated by 'activated' molecular dynamics. Nat Struct Biol (1995) 1.78
Purification and structural characterization of the putative gag-pol protease of human immunodeficiency virus. J Virol (1988) 1.67
Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS (1999) 1.58
In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. Antiviral Res (1996) 1.56
Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease: relationship to drug resistance. Biochemistry (1995) 1.56
Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother (1997) 1.53
Design of enzyme inhibitors using iterative protein crystallographic analysis. J Med Chem (1991) 1.49
Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959. AIDS Res Hum Retroviruses (1995) 1.45
Synthetic peptides as substrates and inhibitors of a retroviral protease. Proc Natl Acad Sci U S A (1988) 1.41
Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex. J Biol Chem (1996) 1.39
Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants. J Biol Chem (1996) 1.34
Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials. J Biol Chem (1995) 1.29
Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells. Antimicrob Agents Chemother (1992) 1.24
Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro. Antimicrob Agents Chemother (1997) 1.23
Effective blocking of HIV-1 proteinase activity by characteristic inhibitors of aspartic proteinases. FEBS Lett (1989) 1.16
HIV drug resistance. Annu Rev Pharmacol Toxicol (1993) 1.14
Studies on the role of the S4 substrate binding site of HIV proteinases. FEBS Lett (1991) 1.14
Emergence of resistant variants of HIV in vivo during monotherapy with the proteinase inhibitor saquinavir. J Antimicrob Chemother (1997) 1.09
Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4+ lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity. Antiviral Res (1996) 1.04
Identification of an amino acid substitution involved in the reduction of sensitivity of HIV-1 to an inhibitor of viral proteinase. Acta Virol (1994) 1.02
Expression of active human immunodeficiency virus type 1 protease by noninfectious chimeric virus particles. J Virol (1991) 1.00
Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother (1996) 0.98
Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease: structure-activity analysis using enzyme kinetics, X-ray crystallography, and infected T-cell assays. Biochemistry (1992) 0.96
In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates. Antimicrob Agents Chemother (1997) 0.95
Impaired infectivity of HIV-1 after a single point mutation in the POL gene to escape the effect of a protease inhibitor in vitro. Virology (1995) 0.89
Activated dynamics of flap opening in HIV-1 protease. Adv Exp Med Biol (1995) 0.83
In vivo selection of HIV-1 variants with reduced susceptibility to the protease inhibitor L-735,524 and related compounds. Adv Exp Med Biol (1996) 0.80
A symmetric inhibitor binds HIV-1 protease asymmetrically. Biochemistry (1993) 0.79
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (1995) 34.97
HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science (1996) 21.81
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 18.10
Decay characteristics of HIV-1-infected compartments during combination therapy. Nature (1997) 13.68
Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science (1998) 12.05
Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med (1999) 7.07
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med (1996) 6.14
Declining blood lead levels and cognitive changes in moderately lead-poisoned children. JAMA (1993) 4.46
Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet (1999) 4.36
The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med (2000) 4.08
Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol (1999) 3.79
HIV-1 drug resistance in newly infected individuals. JAMA (1999) 3.49
Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy. J Exp Med (2001) 3.37
Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy. J Virol (1999) 3.15
Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother (1998) 2.67
Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1. J Virol (1997) 2.60
HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. J Exp Med (1998) 2.50
HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest (1999) 2.42
Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy. J Exp Med (1999) 2.33
The inaccuracy in using interviews to estimate patient reliability in taking medications at home. Med Care (1969) 2.32
Evaluation of the effectiveness of comprehensive and continuous pediatric care. Pediatrics (1971) 2.22
Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy. J Clin Invest (2000) 2.21
Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother (1996) 2.13
Phenotypic changes in drug susceptibility associated with failure of human immunodeficiency virus type 1 (HIV-1) triple combination therapy. J Infect Dis (1999) 1.70
Community advisory boards: their role in AIDS clinical trials. Terry Beirn Community Programs for Clinical Research on AIDS. Health Soc Work (1998) 1.67
Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS (1999) 1.58
Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother (1997) 1.53
Why patients don't follow medical advice: a study of children on long-term antistreptococcal prophylaxis. J Pediatr (1969) 1.50
Studies in the epidemiology and preventability of rheumatic fever. IV. A quantitative determination of compliance in children on oral penicillin prophylaxis. Pediatrics (1969) 1.49
Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy. J Virol (1998) 1.38
A mail-in technique for detecting penicillin in urine: application to the study of maintenance of prophylaxis in rheumatic fever patients. Pediatrics (1968) 1.34
The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection. J Infect Dis (2000) 1.26
Eradication of rheumatic fever: an unfulfilled hope. Circulation (1970) 1.20
Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies. AIDS (1999) 1.18
Improved estimates for HIV-1 clearance rate and intracellular delay. AIDS (1999) 1.17
Molecular tracking of an Human Immunodeficiency Virus nef specific cytotoxic T-cell clone shows persistence of clone-specific T-cell receptor DNA but not mRNA following early combination antiretroviral therapy. Immunol Lett (1999) 1.12
Rapid, transient changes at the env locus of plasma human immunodeficiency virus type 1 populations during the emergence of protease inhibitor resistance. J Virol (1998) 1.10
Human immunodeficiency virus type-1 mRNA splicing pattern in infected persons is determined by the proportion of newly infected cells. Virology (1997) 1.08
Streptococcal pharyngitis: the case for penicillin therapy. Pediatr Infect Dis J (1994) 1.06
The decline of rheumatic fever: role of medical intervention. Lewis W. Wannamaker Memorial Lecture. J Pediatr (1985) 1.06
Circadian rhythms of blood minerals in humans. Science (1981) 1.05
A chronobiologic abnormality in luteinizing hormone secretion in teenage girls with the polycystic-ovary syndrome. N Engl J Med (1983) 1.04
The treatment of pyoderma in children. JAMA (1970) 1.04
Factors involved in treatment failures following oral penicillin therapy of streptococcal pharyngitis. J Pediatr (1968) 1.02
Rheumatic heart disease in developing countries: the consequence of inadequate prevention. Ann Intern Med (1994) 1.02
Accuracy of throat cultures processed in physicians' offices. J Pediatr (1970) 0.98
Management of streptococcal pharyngitis reconsidered. Pediatr Infect Dis (1985) 0.98
An antigenic threshold for maintaining human immunodeficiency virus type 1-specific cytotoxic T lymphocytes. Mol Med (2000) 0.94
The risk of bacterial endocarditis during antirheumatic prophylaxis. JAMA (1967) 0.90
Intrauterine cocaine, lead, and nicotine exposure and fetal growth. Am J Public Health (1994) 0.88
Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection. J Infect Dis (2000) 0.88
Reduced capacity for DNA repair synthesis in patients with or genetically predisposed to colorectal cancer. J Natl Cancer Inst (1983) 0.85
Oxidative stress induces DNA damage and inhibits the repair of DNA lesions induced by N-acetoxy-2-acetylaminofluorene in human peripheral mononuclear leukocytes. Cancer Res (1990) 0.84
Observations on the epidemiology and preventability of rheumatic fever in developing countries. Clin Ther (1981) 0.82
Resistance, fitness, adherence, and potency: mapping the paths to virologic failure. JAMA (2000) 0.81
The use of pressor sensitivity tests for detection of drugs with sympathetic nervous system activity. J Clin Pharmacol J New Drugs (1970) 0.81
Design, synthesis, and resistance patterns of MP-134 and MP-167, two novel inhibitors of HIV type 1 protease. AIDS Res Hum Retroviruses (1996) 0.80
Open-label phase II trial of amprenavir, abacavir, and fixed-dose zidovudine/lamivudine in newly and chronically HIV-1--infected patients. J Acquir Immune Defic Syndr (2001) 0.79
DNA repair synthesis in individuals with and without a family history of cancer. Carcinogenesis (1989) 0.79
Gastric duplication cyst communicating with the pancreatic duct: a rare cause of recurrent abdominal pain. Surgery (1991) 0.78
Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy. Antimicrob Agents Chemother (2001) 0.77
The prevalence of vitamin D deficiency and its relationship with disease severity in an urban pediatric critical care unit. Endocr Regul (2014) 0.77
The Jones criteria for guidance in the diagnosis of rheumatic fever. Another perspective. Arch Pediatr Adolesc Med (1995) 0.77
Parameters influencing measurement of the Gag antigen-specific T-proliferative response to HIV type 1 infection. AIDS Res Hum Retroviruses (2000) 0.76
The fall and rise of rheumatic fever in the United States: a commentary. Int J Cardiol (1988) 0.75
Acute HIV-1 infection: early identification and treatment. Am Fam Physician (1999) 0.75
Rheumatic fever in the United States: no longer a disease of the past. N Z Med J (1988) 0.75
Susceptibility to rheumatic fever. Circulation (1968) 0.75
Population and family planning services: a selected reference guide. J Health Adm Educ (1987) 0.75
The changing picture of rheumatic fever. Arthritis Rheum (1977) 0.75
Management of acute rheumatic fever. Zentralbl Bakteriol Orig (1970) 0.75
Diagnostic significance of edetate disodium calcium testing in children with increased lead absorption. Am J Dis Child (1982) 0.75
Control of streptococcal infections. Priniciples and problems. Minn Med (1975) 0.75
Rheumatic fever. Major Probl Clin Pediatr (1972) 0.75
Rheumatic fever: recent outbreaks of an old disease. Conn Med (1987) 0.75
The effective health care social work director. Soc Work Health Care (1995) 0.75
Common pitfalls in the management of streptococcal infections. Zentralbl Bakteriol Orig (1970) 0.75
Long-acting penicillins: historical perspectives. Pediatr Infect Dis (1985) 0.75
Alcohol misuse as a response to perceived powerlessness in the organization. J Stud Alcohol (1984) 0.75
Sodium nafcillin in the treatment of Group A streptococcal infections. J Pediatr (1967) 0.75
Prevention of rheumatif fever and rheumatic heart disease. J Am Osteopath Assoc (1970) 0.75
Angiographic manifestations of bilateral Wilms' tumor. AJR Am J Roentgenol (1976) 0.75
Adenosine diphosphate ribosyl transferase responses to a standardized dose of hydrogen peroxide in the mononuclear leukocytes of patients with a diagnosis of cancer. Carcinogenesis (1989) 0.75
Rheumatic fever in the eighties. Pediatr Clin North Am (1986) 0.75
Editorial: Partnerships in pediatric graduate education and child care. Conn Med (1975) 0.75
A fatal connective tissue disease following a wasp sting. Am J Dis Child (1967) 0.75
Empathy and communication efficiency. J Soc Psychol (1972) 0.75
Problems in preventing initial attacks of rheumatic fever. Md State Med J (1968) 0.75
A family pediatric clinic at a community hospital. Children (1967) 0.75
Benzathine penicillin G after thirty years. Clin Ther (1980) 0.75
Persistence of group A streptococci as related to penicillinase-producing staphylococci: comparison of penicillin V potassium and sodium nafcillin. J Pediatr (1967) 0.75
DNA repair synthesis as a marker of predisposition to colorectal cancer. Prog Clin Biol Res (1988) 0.75
Rheumatic heart disease and pregnancy in adolescent rheumatic fever patients. Pediatrics (1967) 0.75
Psychologic management of the young orthodontic patient. Angle Orthod (1971) 0.75
PSRO strikes back; let's total up the score. N Y State J Med (1981) 0.75
Streptococcal infections, rheumatic fever and school health services. J Sch Health (1979) 0.75
In search of the Holy Grail: Martin Markowitz, M.D., on the dream of eradication. Res Initiat Treat Action (1998) 0.75
Prevention of rheumatic fever revisited. Pediatr Clin North Am (1971) 0.75
Rheumatic fever. Clin Proc Child Hosp Dist Columbia (1969) 0.75